×
ADVERTISEMENT

SEPTEMBER 20, 2024

Machine Learning Can Predict Best Responders to GLP-1s


Originally published by our sister publication Gastroenterology & Endoscopy News

By Marcus A. Banks

WASHINGTON—Machine learning tools can sift through genetic profiles to predict which patients with obesity will best respond to glucagon-like peptide-1 agonists such as liraglutide (Saxenda/Victoza, Novo Nordisk) or semaglutide (Ozempic/Wegovy, Novo Nordisk), according to a presentation by Mayo Clinic researchers at DDW 2024.

Mayo researchers previously had found that patients with obesity